UBS analyst Ashwani Verma raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $36 from $32 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- ACADIA Pharmaceuticals: Strong Growth and Undervalued Pipeline Support Buy Rating
- ACADIA Pharmaceuticals Reports Strong Q2 2025 Earnings
- Acadia Pharmaceuticals price target raised to $24 from $23 at Mizuho
- Buy Rating on ACADIA Pharmaceuticals Driven by Daybue’s Sales Growth and Market Expansion
- Acadia Pharmaceuticals price target raised to $27 from $23 at BofA